Open AccessTreatment of Geographic Atrophy With Subconjunctival Sirolimus: Results of a Phase I/II Clinical Trial
Author(s) -
Wai T. Wong,
Samuel M. Dresner,
Farzin Forooghian,
Tanya Glaser,
Lauren Doss,
Mei Zhou,
Denise Cunningham,
Katherine Shimel,
Molly Harrington,
Keri Hammel,
Catherine A Cukras,
Frederick L. Ferris,
Emily Y. Chew
Publication year - 2013
Publication title -
investigative ophthalmology and visual science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.935
H-Index - 218
eISSN - 1552-5783
pISSN - 0146-0404
DOI - 10.1167/iovs.13-11650
Subject(s) - medicine , drusen , sirolimus , visual acuity , geographic atrophy , ophthalmology , macular degeneration , adverse effect , clinical trial , randomized controlled trial , retinal , surgery
To investigate the safety and effects of subconjunctival sirolimus, an mTOR inhibitor and immunosuppressive agent, for the treatment of geographic atrophy (GA).